Table 2.
Response to treatment
| Variable | No. of patients | Patients with CR/CRi |
P* | |
|---|---|---|---|---|
| No. | % | |||
| Overall (at least 1 dose of lenalidomide) | 33 | 10 | 30 | |
| Patients completing HD therapy | 19 | 10 | 53 | |
| ECOG PS | .43 | |||
| 0 | 15 | 6 | 40 | |
| 1 | 12 | 3 | 25 | |
| 2 | 4 | 1 | 25 | |
| AML diagnosis | .43 | |||
| De novo | 23 | 6 | 26 | |
| Prior MDS | 8 | 3 | 38 | |
| Treatment-related | 2 | 1 | 50 | |
| Cytogenetic risk category | .13 | |||
| Intermediate | 18 | 5 | 28 | |
| Unfavorable | 13 | 3 | 23 | |
| Unknown | 2 | 2 | 100 | |
| Age, y | .39 | |||
| 60-64 | 6 | 3 | 50 | |
| 65-69 | 8 | 3 | 38 | |
| > 70 | 19 | 4 | 21 | |
| Presenting WBC count (per microliter) | ||||
| < 10 000 | 24 | 10 | 42 | .044 |
| ≥ 10 000 | 9 | 0 | 0 | |
| Presenting BM blast, % | ||||
| Undefined | 2 | 0 | 0 | .003 |
| 20-30 | 8 | 5 | 63 | |
| 31-50 | 7 | 4 | 57 | |
| > 50 | 16 | 1 | 6 | |
| Presenting PB blast count (per microliter) | ||||
| < 1000 | 20 | 10 | 50 | .01 |
| 1000-10 000 | 9 | 0 | 0 | |
| > 10 000 | 4 | 0 | 0 | |
ECOG indicates Eastern Cooperative Oncology Group; and PS, performance status.
*
P values were calculated using Fisher exact test.